The proliferation of legal cannabis across North America has underscored the importance of cannabis genetics and artificial selection.

The legalization of cannabis across major jurisdictions in North America has created a new marketplace for consumer goods. In the modern cannabis industry, we have seen exponential growth in product diversity, including innovative concentrated forms such as oils, soft gel pills, shatter and vape pen cartridges. When it comes to the cannabis flower itself, which also serves as an input for oils and concentrates, the quality and genetic makeup of each strain have become even more important, with major corporations and innovative cannabis companies working to improve their base product. Driven by cannabis connoisseurs and medical users in need of strains that produce unique remedial effects, the legalization of the cannabis industry has caused an explosion of innovation when it comes to cultivating the optimal cannabis plant.

Driven by this product variety, a number of cannabis cultivators and researchers have begun creating uniquely-tailored strains optimized for each particular use-case through the process of artificial selection. Artificial selection has been common practice in farming for centuries, with farmers routinely selecting the best plants and breeding their superior genetics after each crop rotation to improve the following harvest. In the cannabis space, the art of artificial selection and marker-assisted breeding have enabled cultivators to optimize the size, color, smell, density and texture of the resulting cannabis crop. The diversity of cannabis strains currently known to cultivators and researchers has created a new field within the cannabis industry, with licensed producers working alongside researchers and product designers to optimize strains for their unique use-cases and subsequent requirements.

pacroots logoThis INNspired Article is brought to you by:

  PacRoots Cannabis (CSE:PACR) is a British Columbia-based Cannabis Act licensed applicant dedicated to producing premium-quality cannabis products based on high-end selectively bred genetics.Send me an Investor Kit

Cannabis genetics and artificial selection

You don’t have to be a master grower to understand that premium-quality flower is necessary to create premium-quality cannabis concentrates. Just as premium grapes are necessary to create the finest wines, so too are premium flowers a necessary input to create a quality concentrate product. “The starting material is the most important factor in determining the end quality of each extraction. A cannabis plant’s genetics are the starting material and hold extreme value for each strain to reach its potential,” said Will Hyde, cannabis strain specialist and co-host of Leafly’s “What Are You Smoking?” podcast. In addition to the optimal effects enjoyed by recreational uses, the emergence of the medical cannabis market has further emphasized the importance of artificial selection in pursuit of medical strains designed for specific medical needs.

When it comes to quality cannabis flower, consistency is paramount. Due to regulatory requirements and product standards commonly found in North American cannabis markets, major cannabis brands with large-scale operations often select consistent, high-quality cannabis strains for their product lines. The effect, potency, aroma, taste and yield of a cannabis crop can all largely be informed by genetics. “Genetics hold the key to your bud’s effects, flavors, vigor and growth attributes,” said Hyde on his podcast. “Every strain carries a unique genotype that serves as a blueprint for its growth, as well as a specific phenotype that is influenced by its environmental factors and affects a range of strain attributes like color, smell, structure and potency.”

Cannabis genetics enabling strain development

Strategically-minded cannabis producers have recognized the importance of genetics, with a number of licensed producers across the continent working to secure the strains and genetics that can be applied to unique new product designs. In British Columbia, upstart cannabis company PacRoots Cannabis (CSE:PACR) has finalized an agreement to collaborate with cannabis experts at Phenome One, with complete access to the company’s database of over 350 unique cannabis strains that have been carefully field-tested and artificially selected over 30 years of research. “This is a major opportunity for PacRoots to be positioned to offer customers an extensive collection of cannabis cultivars. At PacRoots, we pride ourselves and our customers with quality and we are thrilled with the opportunity to partner with Phenome One, establishing a robust strain portfolio that compares favorably with others in the Canadian cannabis space,” said Patrick Elliott President and CEO of PacRoots.

Phenome One’s extensive database includes proprietary high-THC strains, cannabidiol-dominant strains with rare terpene profiles, and custom strains finely tailored for medical purposes. Moving forward, PacRoots intends to leverage Phenome One’s intellectual property relating to the growing, breeding, and cloning of cannabis cultivars to optimize its offerings. Recently, the COVID-19 pandemic has put a spotlight on efficient operations in the cannabis industry, which PacRoots believes could cause cannabis companies to focus on the genetic profile of their inputs. “The ‘new normal’ has amplified our business, as cultivators demand the efficiency to produce better yields and products for the end-user while maintaining product integrity and potency. Suitable genetics, articular process, and data collection to optimize yield for specific climates are essential to compete in this new global cannabis industry,” said Elliott.

Major producers such as Canopy Growth (NYSE:CGC,TSX:WEED) have long recognized the importance of cannabis genetics in establishing efficient operations. “You can get more yield off of a plant if you can refine the genetics and that allows us to have more grams, more kilograms coming out of this place per year,” said Jordan Sinclair, Canopy Growth’s vice president of communications, during a 2019 interview at the company’s Tweed Farms operations. Following in the footsteps of major producers like Canopy, cannabis genetics specialists such as PacRoots have an opportunity to secure a unique foothold in the cannabis industry by applying science at the greenhouse level.

Takeaway

Whether for medical or recreational use, cannabis companies of all sizes are working to optimize cannabis strains to produce effects tailored to specific use-cases. At the cultivation level, the artificial selection of cannabis strains has also enabled companies to maximize the size of their crops, enabling more efficient operations with every harvest.

This article was originally published by the Investing News Network in July 2020. 


This INNSpired article is sponsored by PacRoots Cannabis (CSE:PACR). This INNSpired article provides information that was sourced by the Investing News Network (INN) and approved by PacRoots Cannabis in order to help investors learn more about the company. PacRoots Cannabis is a client of INN. The company’s campaign fees pay for INN to create and update this INNSpired article.

This INNSpired article was written according to INN editorial standards to educate investors.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services, or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with PacRoots Cannabis and seek advice from a qualified investment advisor.

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a new Florida dispensary, the Company’s 91st nationwide.

The latest dispensary, located in Winter Park , supports Trulieve’s goal of ensuring medical cannabis patients across Florida have safe, reliable access to the medications they rely on. The dispensary expands access throughout Central Florida , joining four locations throughout nearby Orlando .

Keep reading... Show less